Question: PARP inhibitor resistance mechanisms and reversal strategies
BRCA2 reversion mutation frequency in olaparib-resistant ovarian cancer
In audit1 verified (technical)
0/5 publication-ready
Findings metrics
—
total
—
verified
—
pending
—
rejected